GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Return-on-Tangible-Equity

Aptorum Group (Aptorum Group) Return-on-Tangible-Equity : -59.91% (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Aptorum Group's annualized net income for the quarter that ended in Jun. 2023 was $-10.97 Mil. Aptorum Group's average shareholder tangible equity for the quarter that ended in Jun. 2023 was $18.32 Mil. Therefore, Aptorum Group's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 was -59.91%.

The historical rank and industry rank for Aptorum Group's Return-on-Tangible-Equity or its related term are showing as below:

APM' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -79.94   Med: -52.01   Max: 25.28
Current: -68.77

During the past 6 years, Aptorum Group's highest Return-on-Tangible-Equity was 25.28%. The lowest was -79.94%. And the median was -52.01%.

APM's Return-on-Tangible-Equity is ranked worse than
61.42% of 1309 companies
in the Biotechnology industry
Industry Median: -48.28 vs APM: -68.77

Aptorum Group Return-on-Tangible-Equity Historical Data

The historical data trend for Aptorum Group's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Return-on-Tangible-Equity Chart

Aptorum Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Equity
Get a 7-Day Free Trial -49.05 -79.94 25.28 -78.77 -52.01

Aptorum Group Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.02 -67.27 -16.93 -86.07 -59.91

Competitive Comparison of Aptorum Group's Return-on-Tangible-Equity

For the Biotechnology subindustry, Aptorum Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptorum Group's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptorum Group's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Aptorum Group's Return-on-Tangible-Equity falls into.



Aptorum Group Return-on-Tangible-Equity Calculation

Aptorum Group's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-9.8/( (22.727+14.959 )/ 2 )
=-9.8/18.843
=-52.01 %

Aptorum Group's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=-10.974/( (14.959+21.677)/ 2 )
=-10.974/18.318
=-59.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Aptorum Group  (NAS:APM) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Aptorum Group Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptorum Group (Aptorum Group) Business Description

Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group (Aptorum Group) Headlines